Hematological, Biochemical, and Serum Levels of Allergic Mediators in Individuals with and without Allergic Rhinitis

Figures & data

Table 1 Sociodemographic Data of Study Participants According to Groups

Group	Gender	n (%)	Age (years) Median (IQR)
Positive AR	F	8(36.4)	27.5(19.0–37.7)	H(3)=0.446 p=0.931
	M	14(63.6)
	Total	22 (100.0)
AR-SLRT	F	9(42.9)	23.0(18.0–40.0)
	M	12(57.1)
	Total	21(100.0)
n-AR	F	13(65.0)	30.5(18.5–39.0)
	M	7(35.0)
	Total	20(100.0)
Control group	F	11(61.1)	24.0(20.0–34.0)
	M	7(38.9)
	Total	18(100.0)

Abbreviations: AR, Allergic Rhinitis; n-AR, non-allergic rhinitis; AR-SLRT, allergic rhinitis accompanied by symptoms of the lower respiratory tract.

Table 2 Comparison of the Hematological Parameters of the Participants According to Groups

	Group	Mean±SD	F (3, 77)	p
Erythrocyte (million/mm3)	Positive AR	4.75±0.43	3.096	0.032
	AR-SLRT	4.73±0.50
	n-AR	4.81±0.63
	Control group	4.36±0.41
Leukocytes (billion cells/L)	Positive AR	7.94±1.92	1.790	0.156
	AR-SLRT	8.53±1.88
	n-AR	8.93±2.51
	Control group	7.63±1.00
Hemoglobin (grams/L)	Positive AR	143.18±13.44	1.852	0.145
	AR-SLRT	139.28±15.76
	n-AR	139.45±18.40
	Control group	131.50±15.56
Hematocrit (mL/100mL)	Positive AR	40.09±4.02	3.701	0.015
	AR-SLRT	37.97±4.98
	n-AR	40.09±5.80
	Control group	35.57±4.70
MCV(fl)	Positive AR	83.34±3.43	1.366	0.260
	AR-SLRT	81.27±3.16
	n-AR	81.79±4.35
	Control group	82.26±2.65
MCH (pg)	Positive AR	30.15±1.51	1.021	0.388
	AR-SLRT	29.69±3.74
	n-AR	28.99±1.79
	Control group	29.98±1.03
MCHC (gr/dl)	Positive AR	35.89±1.14	2.169	0.099
	AR-SLRT	35.67±1.43
	n-AR	35.12±0.96
	Control group	36.04±1.14
MPV (um3)	Positive AR	7.46±0.72	3.469	0.020
	AR-SLRT	7.25±0.70
	n-AR	7.34±1.12
	Control group	8.09±0.98

Abbreviations: AR, Allergic Rhinitis; n-AR, non-allergic rhinitis; AR-SLRT, allergic rhinitis accompanied by symptoms of the lower respiratory tract; MCV, Mean corpuscular volume; MCH, Mean corpuscular hemoglobin; MCHC, Mean corpuscular hemoglobin concentration; MPV, Mean platelet volume.

Table 3 Comparison of the Leucocyte Formula of the Participants According to Groups

	Group	Mean±SD	F (3, 77)	p
Platelets (billion/L)	Positive AR	208.73±54.76	2.856	0.042
	AR-SLRT	211.81±48.45
	n-AR	246.55±57.94
	Control group	205.17±37.31
Lymphocytes	Positive AR	34.89±9.29	0.103	0.958
	AR-SLRT	35.24±7.33
	n-AR	34.42±7.44
	Control group	35.82±7.56
Monocyte	Positive AR	7.53±1.74	4.943	0.003
	AR-SLRT	8.25±1.00
	n-AR	6.59±1.89
	Control group	6.69±1.56
Neutrophils	Positive AR	58.30±10.11	0.058	0.981
	AR-SLRT	57.81±7.81
	n-AR	57.97±8.56
	Control group	57.14±8.97
RDW	Positive allergic rhinitis	13.76±0.87	0.183	0.908
	Allergic rhinitis with lower tract symptoms	13.98±1.47
	Non-allergic rhinitis	13.73±1.41
	Control group	13.73±1.30
Neutrophils (%)	Positive AR	57.91±8.73	0.157	0.925
	AR-SLRT	58.67±7.79
	n-AR	58.85±10.64
	Control group	59.72±4.96
Lymphocytes (%)	Positive AR	32.82±7.64	0.252	0.860
	AR-SLRT	32.05±6.38
	n-AR	33.95±10.10
	Control group	32.33±4.39
Eosinophils (%)	Positive AR	3.73±2.64	6.144	0.001
	AR-SLRT	4.10±2.39
	n-AR	1.90±1.86
	Control group	1.83±1.34
Monocyte (%)	Positive AR	5.81±1.08	0.826	0.484
	AR-SLRT	5.57±0.75
	n-AR	5.37±1.30
	Control group	5.78±0.73
Basophils (%)	Positive AR	0.00±0.00	NA	NA
	AR-SLRT	0.00±0.00
	n-AR	0.00±0.00
	Control group	0.00±0.00

Abbreviations: AR, Allergic Rhinitis; n-AR, non-allergic rhinitis; AR-SLRT, allergic rhinitis accompanied by symptoms of the lower respiratory tract; RDW, red blood cell distribution width.

Figure 1 The percentage (%) of Eosinophils according to study groups.

Table 4 Comparison of the Total IgE, Periostin, Ft3, Ft4, TSH, Anti-TPO and Vitamin D Parameters of the Participants According to Groups

	Group	Median (IQR)	H (3)	P
Total IgE (IU/mL)	Positive AR	133.1(82.7–320.2)	40.585	<0.0001
	AR-SLRT	243.8(120.5–391.0)
	n-AR	16.0(10.0–89.9)
	Control group	12.5(10.0–34.7)
Ribonuclease A3 (pg/mL)	Positive AR	2216(207.0–269.3)	1.258	0.739
	AR-SLRT	249.9(216.4–279.7)
	n-AR	244.5(204.8–281.0)
	Control group	222.9(200.7–283.7)
Periostin (pg/mL)	Positive AR	40.2(26.7–54.6)	1.595	0.661
	AR-SLRT	42.5(35.3–47.7)
	n-AR	41.99(36.9–47.8)
	Control group	48.4(37.7–55.1)
SLC26A4 (ng/mL)	Positive AR	3.0(2.6–4.0)	4.539	0.209
	AR-SLRT	3.4(2.6–4.3)
	n-AR	3.6(3.2–5.2)
	Control group	3.3(2.9–3.7)
Free T3 (pmol/L)	Positive AR	5.0(4.4–5.5)	5.383	0.146
	AR-SLRT	5.7(4.9–6.0)
	n-AR	5.9(5.0–6.7)
	Control group	4.9(4.7–5.3)
Free T4 (pmol/L)	Positive AR	16.7(15.2–18.0)	3.896	0.273
	AR-SLRT	16.8(15.8–17.7)
	n-AR	17.4(16.5–18.0)
	Control group	17.3–14.7-18.8)
TSH (uIU/mL)	Positive AR	2.5(1.9–3.0)	0.398	0.941
	AR-SLRT	2.74(2.1–2.9)
	n-AR	2.4(1.9–4.1)
	Control group	3.0(1.5–4.2)
Anti TPO (IU/mL)	Positive AR	30.5(21.7–51.1)	1.732	0.630
	AR-SLRT	24.9(21.5–31.5)
	n-AR	35.3(18.2–54.0)
	Control group	22.9(19.2–37.7)
25(OH)D (Vitamin D) (ng/mL)	Positive AR	16.9(11.3–23.9)	7.145	0.067
	AR-SLRT	17.0(14.3–18.8)
	n-AR	17.5(13.2–19.3)
	Control group	12.4(9.5–15.1)

Abbreviations: AR, Allergic Rhinitis; n-AR, non-allergic rhinitis; AR-SLRT, allergic rhinitis accompanied by symptoms of the lower respiratory tract.

Figure 2 Total IgE (UI/mL) median values according to study groups.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.